The Chaim Sheba Medical Center
The Chaim Sheba Medical Center
Ramat Gan, Israel11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06888921 | |
| Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06408935 | |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06233461 | |
| A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) | Hemolytic Disease of the Fetus and Newborn | Recruiting | Phase 3 | 2026-09-25 | NCT05912517 | |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05197049 | |
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Active, not recruiting | Phase 3 | 2026-09-22 | NCT06081894 | |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Abnormalities, Multiple, Barth syndrome, Bone Marrow Failure Disorders, Cardiovascular Abnormalities, Cohen syndrome, Congenital Abnormalities, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Digestive System Diseases, Hemic and Lymphatic Diseases, Kostmann syndrome, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, Shwachman-Diamond syndrome, X-linked disease, agranulocytosis, autoimmune disease, bone marrow disorder, cardiovascular disorder, congenital heart disease, exocrine pancreatic insufficiency, heart disorder, hematologic disorder, hereditary disease, immune system disorder, inborn errors of metabolism, leukocyte disorder, leukopenia, lipomatosis, metabolic disease, neutropenia, pancreas disorder | Recruiting | Phase 3 | 2026-08-06 | NCT06056297 | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Recruiting | Phase 2 | 2026-07-22 | NCT04879329 | |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder | Active, not recruiting | Phase 3 | 2026-05-27 | NCT04704934 | |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | aortic valve disorder, aortic valve stenosis, cardiomyopathy, cardiovascular disorder, heart disorder, heart valve disorder, hypertrophic cardiomyopathy, subvalvular aortic stenosis | Enrolling by invitation | Phase 2 / Phase 3 | 2026-01-22 | NCT04848506 | |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | low grade glioma | Recruiting | Phase 2 | 2025-04-10 | NCT04775485 |